Zinthoma, Antiretroviral and Nausea and Vomiting

Phase 4

• Conditions: B20-B24; Human immunodeficiency virus [HIV] disease; HIV/AIDS.

• Registration Number: IRCT201305283449N12
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Inclusion Criteria: HIV positive patients who are candidate for Antiretroviral therapy and who signe study consent form.
Exclusion criteria: History of zinthoma or othera herbal products hypersensitivity

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of Nausea and Vomoting. Timepoint: During 2 weeks of starting antiretroviral. Method of measurement: Visual analouge scale.

Secondary Outcome Measures

Name	Time	Method
Severity of nausea. Timepoint: Dring 2 weeks of starting antiretroviral. Method of measurement: Visual analogue scale.